{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T20:24:57Z","timestamp":1754598297896},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1093\/ndt\/gfs519","type":"journal-article","created":{"date-parts":[[2012,12,8]],"date-time":"2012-12-08T02:40:56Z","timestamp":1354934456000},"page":"242-244","source":"Crossref","is-referenced-by-count":14,"title":["mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open"],"prefix":"10.1093","volume":"28","author":[{"given":"Meg J.","family":"Jardine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thaminda","family":"Liyanage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Buxton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,12,5]]},"reference":[{"key":"key\n\t\t\t\t20170518085802_GFS519C1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ki.2009.128","article-title":"Autosomal dominant polycystic kidney disease: the last 3 years","volume":"76","author":"Torres","year":"2009","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20170518085802_GFS519C2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/MNH.0b013e3283262ab0","article-title":"Advances in the pathogenessis and treatment of polycystic kidney disease","volume":"18","author":"Patel","year":"2009","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"key\n\t\t\t\t20170518085802_GFS519C3","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1681\/ASN.2006121387","article-title":"Comprehensive molecular diagnostic in autosomal dominant polycystic kidney disease","volume":"18","author":"Rossetti","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170518085802_GFS519C4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","article-title":"Comparison of phenotypes of polycystic kidney disease types 1 and 2","volume":"353","author":"Hateboer","year":"1999","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170518085802_GFS519C5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrneph.2010.18","article-title":"Molecular diagnostics for autosomal dominant polycystic kidney disease","volume":"6","author":"Harris","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"key\n\t\t\t\t20170518085802_GFS519C6","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9 Suppl","key":"key\n\t\t\t\t20170518085802_GFS519C7","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.transproceed.2010.07.008","article-title":"Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease","volume":"42","author":"Wuthrich","year":"2010","journal-title":"Transplant Proc"},{"key":"key\n\t\t\t\t20170518085802_GFS519C8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.ackd.2010.01.006","article-title":"Treatment strategies and clinical trial design in ADPKD","volume":"17","author":"Torres","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"key\n\t\t\t\t20170518085802_GFS519C9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1681\/ASN.2007050626","article-title":"Sirolimus reduces polycystic liver volume in ADPKD patients","volume":"19","author":"Qian","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170518085802_GFS519C10","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170518085802_GFS519C11","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170518085802_GFS519C12","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170518085802_GFS519C13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1056\/NEJMe1006925","article-title":"mTOR inhibitors in polycystic kidney disease","volume":"363","author":"Watnick","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170518085802_GFS519C14","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nrneph.2010.153","article-title":"Polycystic kidney disease: do mTOR inhibitors still have a future in ADPKD?","volume":"6","author":"Perico","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"key\n\t\t\t\t20170518085802_GFS519C15","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/j.1600-6143.2010.03152.x","article-title":"Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?","volume":"10","author":"Canaud","year":"2010","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20170518085802_GFS519C16","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1681\/ASN.2009121302","article-title":"Sirolimus therapy to halt the progression of ADPKD","volume":"21","author":"Perico","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170518085802_GFS519C17","article-title":"NCT00286156: Pilot study of rapamycin as treatment for autosomal dominant polycystic kidney disease (ADPKD) [database on the Internet]"},{"key":"key\n\t\t\t\t20170518085802_GFS519C18","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1093\/ndt\/gfs264","article-title":"Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study","volume":"27","author":"Stallone","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20170518085802_GFS519C19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/j.ackd.2009.12.004","article-title":"Determinants of renal disease variability in ADPKD","volume":"17","author":"Harris","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"key\n\t\t\t\t20170518085802_GFS519C20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2215\/CJN.04310709","article-title":"The HALT polycystic kidney disease trials: design and implementation","volume":"5","author":"Chapman","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170518085802_GFS519C21","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","article-title":"Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3\u20134 Study","volume":"57","author":"Torres","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20170518085802_GFS519C22","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/28\/2\/242\/12852346\/gfs519.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T04:41:17Z","timestamp":1503549677000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article-lookup\/doi\/10.1093\/ndt\/gfs519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,5]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,12,5]]},"published-print":{"date-parts":[[2013,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfs519","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12,5]]}}}